GHRP-2

Pralmorelin (GHRP-2) hexapeptide research reference · approved Japanese diagnostic product context is not transferable

Lot-specific chromatographic purity and quantitative peptide content; confirm both on the released-lot COA · target, verify batch COACAS 158861-67-7RUO

Research statusHuman diagnostic and PK literature exists for specific protocols/products; this material is laboratory Research Use Only

Supplied formLinear amidated hexapeptide containing D-2-naphthylalanine

Lead time10–18 days

GHRP-2 — Lot-specific lyophilized research peptide; confirm colour and physical form on the released-lot COA

GHRP-2 — Lot-specific lyophilized research peptide; confirm colour and physical form on the released-lot COA · Representative packaging image · verify the ordered lot

Representative packaging image · verify the ordered lot

Decision summary

Key benefits

Research applications include GHS-R1a pharmacology, GH-secretagogue assay development, receptor-signalling comparisons, qualified PK/PD method work, food-intake research and anti-doping analytical methods
Human diagnostic-study effects are protocol context, not anabolic, body-composition, recovery or treatment benefits of this lot.

Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS: 158861-67-7
Formula: C₄₅H₅₅N₉O₆
Molecular weight: Approximately 817.98 Da
Appearance: Lot-specific lyophilized research peptide; confirm colour and physical form on the released-lot COA
Purity: Lot-specific chromatographic purity and quantitative peptide content; confirm both on the released-lot COA · target, verify batch COA
Storage: Follow the released-lot COA, SDS and formulation-specific stability statement. Temperature, shipping range, container and prepared-solution hold time require evidence for the exact sequence, salt/counterion, matrix and concentration; no universal 2–8 °C or post-reconstitution rule applies.
MOQ: On request
Lead time: 10–18 days

PubChem CID 6918245

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Define long-term storage and transit exposure separately. Cold-chain can be quoted when the buyer’s risk assessment requires it and adds cost.

Research context

What researchers study about GHRP-2

GHRP-2, also called pralmorelin or KP-102, is the amidated hexapeptide D-Ala-D-2Nal-Ala-Trp-D-Phe-Lys-NH₂ and a GHS-R1a agonist. PubChem and NCATS support formula C₄₅H₅₅N₉O₆, molecular weight about 817.98 Da and CAS 158861-67-7 for pralmorelin. PMDA records the Japanese finished diagnostic product GHRP Kaken 100 as pralmorelin hydrochloride and reports a dihydrochloride mass basis of 890.90 Da; that product approval, formulation and instructions do not transfer to a separately supplied RUO lot or other jurisdictions. FDA records an orphan-drug designation but explicitly lists pralmorelin hydrochloride as not approved for the orphan indication. GHRP-2 is prohibited at all times under the 2026 WADA List.

Sequence and stereochemistry qualification
GHS-R1a receptor and signalling assays
GH-secretagogue PK/PD method research; controlled food-intake research; diagnostic-reference comparison; and LC-MS/MS anti-doping method development
These are research applications, not clinical or performance indications.

Mechanism context

The question the literature is testing

GHRP-2 agonism at GHS-R1a can stimulate GH release through signalling distinct from GHRH. Controlled human work also measured increased food intake. Response magnitude and off-axis endocrine findings depend on population, exposure, route and protocol. Mechanistic rationale for combining GHRP-2 with GHRH analogues does not establish a safe or preferred commercial combination.

Evidence map

Research routes and exposure context

Evidence tierHuman clinical research

Research areaGrowth-hormone axis research

Routes reported in sources

Intravenous

Dose / exposure contextProtocol-specific; verify the cited primary source

Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

Not for human or veterinary use
Human studies of specific diagnostic/research protocols do not establish safety for this lot, long-term use, repeated exposure or combinations
GH-axis, appetite, glucose, cortisol and prolactin effects are protocol-dependent
GHRP-2/pralmorelin is prohibited at all times under the 2026 WADA List
Follow the SDS and institutional controls.

Interactions reported in the literature

No patient combination or drug-interaction guidance is provided
Pairings with GHRH analogues, other GHS-R1a agonists, insulin or tissue-repair peptides require an approved research protocol and do not establish synergy, compatibility or safety.

Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Factory batch documentation

GHRP-2 factory batch COAs

GHRP-2 5 mg Factory batch COA protected preview

GHRP-25 mg · WHJLP-G255-260424-D

GHRP-2 10 mg Factory batch COA protected preview

GHRP-210 mg · WHJLP-G2510-260423-D

GHRP-2 15 mg Factory batch COA protected preview

GHRP-215 mg · WHJLP-G2515-260421-C

Representative records, refreshed periodically

Published COAs show representative factory batches and may not be the latest available. For a current quote or shipment, our sales team can confirm the applicable lot and provide its COA.

Independent testing, arranged on request

Third-party reports are not routinely published. If independent verification is required, we can agree the laboratory, method, acceptance criteria and remedy before testing. If the agreed specification is not met, an appropriate resolution—including a refund where applicable—can be discussed under the agreed terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Help reviewing your COA

Need help reading a factory COA or third-party report? Our sales team can clarify test items, specifications and how the results relate to the lot under discussion.

Ask for the current packet, not a generic certificate

Require exact amidated sequence and D-stereochemistry, D-2-naphthylalanine identity, free-base or salt assignment, theoretical and observed intact mass, orthogonal sequence evidence, stability-indicating HPLC purity and impurity profile, quantitative peptide content, counterion/water/residual solvents and lot-specific stability
Sterility and endotoxin are separate tests
Appetite response or solution appearance is not quality control.

Released-batch COARP-HPLC result and method contextIdentity result appropriate to the moleculeWater / counter-ion context where relevantSDS and handling statementAdditional testing scoped on request

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack

GHRP2-05MG5 mg10 vials

GHRP2-10MG10 mg10 vials

GHRP2-15MG15 mg10 vials

Handling

Storage in the lab and temperature during transit are different decisions

Follow the released-lot COA, SDS and formulation-specific stability statement. Temperature, shipping range, container and prepared-solution hold time require evidence for the exact sequence, salt/counterion, matrix and concentration; no universal 2–8 °C or post-reconstitution rule applies.

State destination, season, acceptable transit exposure and whether your protocol requires insulated or cold-chain service. Additional temperature-control cost is quoted explicitly.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. Testing must be performed by a mutually accepted, established specialist laboratory. Fee allocation, specification, sampling, method and acceptance rule must be agreed before testing; if an agreed independent result shows nonconformance, the remedy follows the signed order terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

Is cold-chain shipping always required?+

Not always. Heat can accelerate degradation, especially during summer and long transit. Cold-chain reduces exposure but raises cost. State the destination and stability risk so the right service can be quoted.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices IATA Temperature Control Regulations ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls

These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

Identity: NIH PubChem CID 6918245 and NCATS/FDA UNII E6S6E1F19M; CID 5493556 is a related record with an acetate-associated synonym caveat. Japanese product context: PMDA approval and current label records for pralmorelin hydrochloride/GHRP Kaken 100. U.S. context: FDA orphan-drug record, which explicitly says not FDA approved for the orphan indication. Human PK/PD: Pihoker et al. 1998, PMID 9543135. Food-intake study: Laferrère et al. 2005, PMID 15699539 / PMCID PMC2824650. Analytical context: PMID 20552695. Sport status: official 2026 WADA Prohibited List. Each value must retain its exact chemical form, product, population, route and protocol.

01
Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN
Drugs in R&D · 2004 · peer-reviewed drug-development profile review
Open source
02
Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2: a phase I study in children
Journal of Clinical Endocrinology & Metabolism · 1998 · peer-reviewed original research (Phase I clinical study)
Open source
03
Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children
Journal of Clinical Endocrinology & Metabolism · 1998 · peer-reviewed original research (clinical trial)
Open source
04
Growth Hormone Releasing Peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men
Journal of Clinical Endocrinology & Metabolism · 2005 · peer-reviewed original research
Open source
05
Ghrelin receptor agonist, GHRP-2, produces antinociceptive effects at the supraspinal level via the opioid receptor in mice
Peptides · 2014 · peer-reviewed original research (preclinical/animal study)
Open source
06
The arginine and GHRP-2 tests as alternatives to the insulin tolerance test for the diagnosis of adult GH deficiency in Japanese patients: a comparison
Endocrine Journal · 2013 · peer-reviewed original research (comparative clinical study)
Open source
07
Investigation of the clinical significance of the growth hormone-releasing peptide-2 test for the diagnosis of secondary adrenal failure
Endocrine Journal · 2016 · peer-reviewed original research
Open source
08
Clinical Usefulness of the Growth Hormone-Releasing Peptide-2 Test for Hypothalamic-Pituitary Disorder
Journal of the Endocrine Society · 2022 · peer-reviewed original research
Open source

Product FAQ

Questions buyers ask about GHRP-2

What identity attributes distinguish GHRP-2/pralmorelin?+

Confirm the amidated hexapeptide D-Ala-D-2Nal-Ala-Trp-D-Phe-Lys-NH₂, D-residue stereochemistry, D-2-naphthylalanine identity, free-peptide or salt form, counterion, formula C₄₅H₅₅N₉O₆ and observed mass near the 817.98 Da free-peptide convention. PMDA documents identify the Japanese finished product as pralmorelin hydrochloride and report a dihydrochloride mass basis of 890.90 Da. PubChem and NCATS support CAS 158861-67-7 for pralmorelin; a name or registry number alone does not qualify a lot.

What are the regulatory and sport boundaries?+

PMDA records the pralmorelin-hydrochloride finished diagnostic product GHRP Kaken 100 in Japan; that status does not approve this RUO lot or transfer to other countries. FDA records an orphan-drug designation for pralmorelin hydrochloride but explicitly lists it as not FDA approved for the orphan indication; designation is not approval. The 2026 WADA List prohibits GH-releasing peptides, including GHRP-2/pralmorelin, at all times; no performance-use or detection-evasion information is provided.

GHRP-2

Key benefits

Specifications to confirm against the released lot

Identity, purity and content are separate release questions.

What researchers study about GHRP-2

The question the literature is testing

Research routes and exposure context

Compatibility, limitations and decision context

Interactions reported in the literature

GHRP-2 factory batch COAs

Ask for the current packet, not a generic certificate

Quote the fill and pack configuration you need

Storage in the lab and temperature during transit are different decisions

Terms to settle before the purchase order

Literature behind the research context

Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN

Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2: a phase I study in children

Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children

Growth Hormone Releasing Peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men

Ghrelin receptor agonist, GHRP-2, produces antinociceptive effects at the supraspinal level via the opioid receptor in mice

The arginine and GHRP-2 tests as alternatives to the insulin tolerance test for the diagnosis of adult GH deficiency in Japanese patients: a comparison

Investigation of the clinical significance of the growth hormone-releasing peptide-2 test for the diagnosis of secondary adrenal failure

Clinical Usefulness of the Growth Hormone-Releasing Peptide-2 Test for Hypothalamic-Pituitary Disorder

Questions buyers ask about GHRP-2

Compare adjacent molecules and documentation needs.

GHRP-6

Ipamorelin

Sermorelin

Tesa+IP5